subject: Cri-report - Risk Reward Of Developing A Herceptin Biosimilar A Thorough Assessment [print this page] (CRi-report) -Herceptin exclusivity is expiring in major geographies and many Biosimilar players (both experienced and new entrant) are looking to have a share of this potential $6billion pie. Herceptin sales are critical to Roche as it comprise about 15% of its cumulative Pharma sales. While eying for this potential lucrative opportunity, there are several risks and barriers that Biosimilar players should be aware. The report Risk Reward of Developing a Herceptin biosimilar A thorough assessment looks into several aspects of potential opportunity size for Biosimilar players, with regard to:
- European Experience of Biosimilars
- Current market positioning of Herceptin across geography
- Different technologies deployed by biosimilar players
- Competition Pipeline of Biosimilar and Biobetters targeting Herceptin
- Potential Market Expansion post expiry of Market Exclusivity
- Defense Strategies deployed by Roche
- Ongoing Clinical trials and their impact on Market Opportunity
- Global Regulatory Process and Hurdles
- Risk/Reward profile of developing Herceptin biosimilar
Full report: http://www.cri-report.com/biotechnology/5489-risk-reward-of-developing-a-herceptin-biosimilar-a-thorough-assessment.html
Table of Contents
1. Executive Summary
2. European experience of Biosimilar launch
- Pricing
- Market share dynamics
3. Introduction- Herceptin
- Geography-wise Sales Forecast until patent expiry
- Patent expiries in major geographies
- Pricing in major geographies
- Penetration in major emerging markets
- Expected market expansion post patent expiry
- Ongoing Clinical trials on Herceptin
4. About the biosimilar space
- Different technologies deployed by biosimilar players
- Partnering deals in biosimilar
- Cost of developing biosimilar/biobetter
- Comparison USFDA and EUROPE biosimilar guideline
- Requirement of Analytical methods
- Interchangeability and substitution
- Regulatory review process for biosimilar- Principle and Concepts
- Bridging Studies- A way to reduce the launch timeline in multiple geographies
- Importance of post-marketing safety in Non-ICH countries
- A brief on biosimilar approval guidelines in geographies other than US and Europe
5. Pipeline of Herceptin Biosimilar and Biobetters
- Ongoing Clinical trials on Herceptin biosimilar/biobetter
- A brief on companies developing Herceptin biosimilar
- Financial capability
- Technical capability
6. Opportunities and Threats for Herceptin Biosimilar
- Defense strategy by Roche to woo away biosimilar threat in global markets and Emerging markets
- Major clinical trials on Herceptin- potential impact on its future sales
- Physician's and Payers adaptation for using Biosimilar
- Competitive threats - Upcoming biobetters and novel biologics in HER2+ve Breast cancer and Gastric cancer
7. Our view on Risk/Reward profile of developing Herceptin Biosimilar
Full report: http://www.cri-report.com/biotechnology/5489-risk-reward-of-developing-a-herceptin-biosimilar-a-thorough-assessment.html
